925 related articles for article (PubMed ID: 14669293)
1. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.
Ansarin H; Daliri M; Soltani-Arabshahi R
Eur J Dermatol; 2006; 16(5):543-7. PubMed ID: 17101476
[TBL] [Abstract][Full Text] [Related]
3. Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck.
Staibano S; Lo Muzio L; Pannone G; Scalvenzi M; Salvatore G; Errico ME; Fanali S; De Rosa G; Piattelli A
Anticancer Res; 2001; 21(6A):3757-64. PubMed ID: 11911244
[TBL] [Abstract][Full Text] [Related]
4. Histologic safety margin in basal cell carcinoma of the eyelid: correlation with recurrence rate.
Auw-Haedrich C; Frick S; Boehringer D; Mittelviefhaus H
Ophthalmology; 2009 Apr; 116(4):802-6. PubMed ID: 19232734
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
Allal AS; Waelchli L; Bründler MA
Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
[TBL] [Abstract][Full Text] [Related]
6. High recurrence rates of Basal cell carcinoma after mohs surgery in patients with chronic lymphocytic leukemia.
Mehrany K; Weenig RH; Pittelkow MR; Roenigk RK; Otley CC
Arch Dermatol; 2004 Aug; 140(8):985-8. PubMed ID: 15313816
[TBL] [Abstract][Full Text] [Related]
7. [Immunomorphological features of cutaneous basal-cell carcinoma].
Chuprov IN
Vopr Onkol; 2008; 54(6):715-9. PubMed ID: 19241845
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining for Ber-EP4, p53, proliferating cell nuclear antigen, Ki-67, bcl-2, CD34, and factor XIIIa in nevus sebaceus.
Barrett TL; Smith KJ; Williams J; Corner SW; Hodge JJ; Skelton HG
Mod Pathol; 1999 May; 12(5):450-5. PubMed ID: 10349981
[TBL] [Abstract][Full Text] [Related]
9. HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy.
Urosevic M; Kempf W; Zagrodnik B; Panizzon R; Burg G; Dummer R
Clin Exp Dermatol; 2005 Jul; 30(4):422-5. PubMed ID: 15953086
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
11. Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma.
Ramachandran S; Rajaratnam R; Smith AG; Lear JT; Strange RC
J Am Acad Dermatol; 2009 Aug; 61(2):247-51. PubMed ID: 19481292
[TBL] [Abstract][Full Text] [Related]
12. Combined CO(2) laser with photodynamic therapy for the treatment of nodular basal cell carcinomas.
Whitaker IS; Shokrollahi K; James W; Mishra A; Lohana P; Murison MC
Ann Plast Surg; 2007 Nov; 59(5):484-8. PubMed ID: 17992139
[TBL] [Abstract][Full Text] [Related]
13. Basal cell carcinoma in a series of renal transplant recipients: epidemiology and clinicopathologic features.
Mertz KD; Proske D; Kettelhack N; Kegel C; Keusch G; Schwarz A; Ambühl PM; Pfaltz M; Kempf W
Int J Dermatol; 2010 Apr; 49(4):385-9. PubMed ID: 20465691
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
[TBL] [Abstract][Full Text] [Related]
15. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.
Rodriguez-Vigil T; Vázquez-López F; Perez-Oliva N
J Am Acad Dermatol; 2007 Jan; 56(1):91-5. PubMed ID: 17190625
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
[TBL] [Abstract][Full Text] [Related]
17. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas.
Betti R; Menni S; Radaelli G; Bombonato C; Crosti C
J Dermatol; 2010 Jul; 37(7):611-6. PubMed ID: 20629826
[TBL] [Abstract][Full Text] [Related]
18. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes.
McCormack CJ; Kelly JW; Dorevitch AP
Arch Dermatol; 1997 May; 133(5):593-6. PubMed ID: 9158412
[TBL] [Abstract][Full Text] [Related]
19. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up.
Malhotra R; Huilgol SC; Huynh NT; Selva D
Ophthalmology; 2004 Apr; 111(4):631-6. PubMed ID: 15051193
[TBL] [Abstract][Full Text] [Related]
20. Comparative morphometric analysis of primary versus recurrent basal cell carcinoma and of histological subtypes. Significance of morphometry of the nuclei.
Bierhoff E; Appel K; Appel T; Buettner R; Wardelmann E
Anticancer Res; 2003; 23(3B):2697-700. PubMed ID: 12894560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
